Paper Details

  1. Home
  2. Paper Details

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

Author: AsciertoPaolo A, CaroIvor, DemidovLev, EigentlerThomas, GogasHelen, GutzmerRalf, HertigChristian, KustersLieke, LewisKarl, McArthurGrant A, PereiraRodrigo P, ProtsenkoSvetlana, RobertCaroline, RutkowskiPiotr, SchachterJacob, StroyakovskiyDaniil, XueCloris, YanYibing, ZhukovaNatalia

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study reports the results of a second, prespecified, interim overall survival analysis of the phase 3 IMspire150 study. The primary analysis showed improved progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib compared to placebo, vemurafenib, and cobimetinib in patients with BRAF<sup>V600</sup> mutation-positive melanoma.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAF<sup>V...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(22)00687-8

データ提供：米国国立医学図書館（NLM）

Atezolizumab for Advanced Melanoma: A New Oasis in the Desert of Treatment

Melanoma, a type of skin cancer, is a formidable foe that can be difficult to treat. This study investigates the efficacy of atezolizumab, an immunotherapy drug, in combination with vemurafenib and cobimetinib for patients with BRAFV600 mutation-positive advanced melanoma.

A Beacon of Hope

The study found that atezolizumab, in combination with other targeted therapies, significantly improved progression-free survival compared to a placebo group. This is like finding a beacon of light in the vast desert of melanoma, offering hope for a more favorable course of the disease.

Navigating the Desert of Cancer

The study suggests that atezolizumab, in combination with vemurafenib and cobimetinib, could be a promising treatment option for patients with BRAFV600 mutation-positive advanced melanoma. This is like finding a well-traveled path through the desert of cancer, potentially leading to a more manageable journey and improved outcomes.

Dr. Camel's Conclusion

This study offers encouraging news for patients with melanoma, highlighting the potential of immunotherapy to enhance treatment effectiveness and improve survival. This research represents a significant step forward in the battle against melanoma, offering a glimmer of hope in the desert of cancer.
Date :
  1. Date Completed 2023-01-09
  2. Date Revised 2023-02-15
Further Info :

Pubmed ID

36460017

DOI: Digital Object Identifier

10.1016/S1470-2045(22)00687-8

Related Literature

Article Analysis
・Effects of cobimetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.